Multiple diffuse physiological pathways in colonic mucosa

Multiple diffuse physiological pathways in colonic mucosa is a descriptive term used in clinical pharmacology to define the localized, multi-targeted action of 5-aminosalicylates (5-ASA) within the intestinal lining (FDA Label: Asacol, 2021). This concept does not represent a single molecular target but rather a suite of physiological processes, including the inhibition of cyclooxygenase and lipoxygenase enzymes, which reduces the synthesis of pro-inflammatory prostaglandins and leukotrienes (StatPearls: Mesalamine, 2023). These pathways also involve the scavenging of free radicals and the activation of peroxisome proliferator-activated receptor gamma (PPAR-gamma) to maintain mucosal integrity (PubChem: CID 4048). Drugs interacting with these pathways, such as mesalamine and sulfasalazine, are primarily used to manage inflammatory bowel diseases like ulcerative colitis. The modulation of these pathways is critical for reducing the chronic inflammation associated with ulcerative colitis and Crohn's disease. Because the term describes a broad mechanism of action and a physiological site rather than a specific protein or receptor, it is not classified as a discrete therapeutic target in modern molecular pharmacology.

Other names

Colonic mucosal pathwaysDiffuse colonic physiological processesLocal colonic anti-inflammatory pathways

Local inhibition of cyclooxygenase and lipoxygenase enzymes, scavenging of reactive oxygen species, and activation of PPAR-gamma.